The company said its officers plan to reaffirm full-year 2024 diluted net income guidance of greater than $34.29 per diluted share in meetings with investors over the coming weeks. That figure includes approximately $2.81 per diluted share of net unfavorable items.

1. 01

   The company said its officers plan to reaffirm full-year 2024 diluted net income guidance of greater than $34.29 per diluted share in meetings with investors over the coming weeks. That figure includes approximately $2.81 per diluted share of net unfavorable items.

2. 02

   The company said it continues to expect adjusted net income of greater than $37.10 per diluted share, excluding those items. This outlook relates to full-year 2024.

3. 03

   The company said the Centers for Medicare & Medicaid Services (CMS) informed it that four of its Medicare Advantage contracts will have a higher 2024 Star Rating, as CMS updated the original ratings announced in October 2023.

4. 04

   The company estimated that approximately 49% of its Medicare Advantage members, based on January 2024 enrollment, are in plans rated at least 4-Star for the 2024 Star Ratings (payment year 2025). It estimated the financial benefit of the reconsideration decision on payment year 2025 revenue at approximately $190 million.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.